Given the axis’s potential role in promoting EMT, cellular migration, and survival signaling, targeting the WISP1/Src/MIF pathway presents a promising therapeutic approach to combat aggressive ER-Positive breast cancer and may help overcome treatment resistance. This evidence concerns the gene MIF and breast cancer.